I-Corps: Injectable, Highly Sticky, Antimicrobial, and Hemostatic Adhesive for Cornea Injury Repair

I-Corps：用于角膜损伤修复的可注射、高粘性、抗菌和止血粘合剂

• 批准号: 1848656
• 负责人: Iman Noshadi
• 金额: $ 5万
• 依托单位: Rowan University
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-15 至 2019-02-28
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1848656&HistoricalAwards=false
• 关键词: Corps; Injectable; Highly; Sticky; Antimicrobial

The broader impact/commercial potential of this I-Corps project targets treatment of ocular trauma, in particular corneal injuries. Ocular trauma treatment requires advanced surgical equipment and specialty surgical centers. The Corneal Transplant Market, currently at 40000 per year in the US is expected to grow at 10.8% from 2017 to 2023. The project targets the wound care market of $18.22 billion (2016), expected to reach $26.24 billion (2023). The societal impact entails enabling rapid care provision to patients like soldiers in combat, to trauma and elderly and pediatric patients, as well as reduction of operative and post-operative costs. The technology can be extended to repairing tissues such as lung, liver, heart or kidneys, expanding its reach and medical benefits to larger populations. This novel chemistry platform aims toward tissue adhesion, but the chemistry could be slightly altered to make materials for a broader range of biomedical applications. Study of such novel material platforms, like understanding of structure-property relationships, offers numerous teaching and outreach opportunities involving students from subject disciplines spanning chemistry, material sciences, chemical, mechanical, and electrical engineering to biology. This I-Corps project has developed a modified hydrogel to make antimicrobial, hemostatic and highly adhesive glue for surgical applications. This is a material platform to make cost-effective, sutureless, and user-friendly adhesives to heal injury to biological tissue and save operative and post-operative time and cost. The current primary needs for ocular trauma surgery entail operative and postoperative time and cost reduction. Currently, there are no such Food and Drug Administration-approved material platforms to replace the presently used techniques of suturing effectively. The material is expected to enjoy biocompatibility, biodegradability, no toxicity and excellent adhesion to tissues, even in the presence of body fluids. The platform may also aid in blood coagulation, facilitate healing and inhibit bacterial growth. This innovation will potentially circumvent the limitations of current surgical and post-operative approaches in corneal repair, and in the future may be extended to repair of other human tissues.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

I-Corps项目的更广泛影响/商业潜力针对眼部创伤的治疗，特别是角膜损伤。眼外伤的治疗需要先进的手术设备和专业的手术中心。从2017年到2023年，美国的角膜移植市场预计将以每年4万例的速度增长10.8%。项目目标创面护理市场规模为182.2亿美元（2016年），预计达到262.4亿美元（2023年）。其社会影响包括为战斗中的士兵、创伤患者、老年人和儿科患者等患者提供快速护理，以及降低手术和术后费用。这项技术可以扩展到修复肺、肝脏、心脏或肾脏等组织，扩大其覆盖范围，并为更多人带来医疗效益。这种新颖的化学平台旨在组织粘附，但化学可以稍微改变，以制造更广泛的生物医学应用材料。对这种新型材料平台的研究，如对结构-性质关系的理解，为化学、材料科学、化学、机械、电气工程和生物学等学科的学生提供了大量的教学和推广机会。这个I-Corps项目开发了一种改良的水凝胶，用于生产抗菌、止血和高度粘合的外科应用胶水。这是一种材料平台，可以制造成本效益高、无缝合线、用户友好的粘接剂，用于愈合生物组织损伤，节省手术和术后时间和成本。目前眼外伤手术的主要需求是减少手术和术后的时间和成本。目前，还没有这样一种食品药品监督管理局批准的材料平台来有效地取代目前使用的缝合技术。该材料有望具有生物相容性、可生物降解性、无毒性和对组织的良好粘附性，即使在存在体液的情况下也是如此。该平台还可以帮助血液凝固，促进愈合和抑制细菌生长。这一创新将潜在地规避当前手术和术后角膜修复方法的局限性，并在未来可能扩展到其他人体组织的修复。该奖项反映了美国国家科学基金会的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。